Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 1430
- Registration Number
- NCT02649478
- Locations
- 🇺🇸
Roxane Laboratories Research Site #22, Spartanburg, South Carolina, United States
🇺🇸Roxane Laboratories Research Site #84, Bakersfield, California, United States
🇺🇸Roxane Laboratories Research Site #95, Columbus, Ohio, United States
Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 26
- Registration Number
- NCT01903122
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Las Vegas, Nevada, United States
Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 27
- Registration Number
- NCT01903109
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Las Vegas, Nevada, United States
Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed Conditions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 34
- Registration Number
- NCT01712100
- Locations
- 🇺🇸
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States
Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 37
- Registration Number
- NCT01712139
- Locations
- 🇺🇸
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States
Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fasted Conditions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 33
- Registration Number
- NCT01712113
- Locations
- 🇺🇸
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States
Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 40
- Registration Number
- NCT01712126
- Locations
- 🇺🇸
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States
Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 59
- Registration Number
- NCT01703468
- Locations
- 🇺🇸
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States
Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 64
- Registration Number
- NCT01702623
- Locations
- 🇺🇸
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States
A Study of Oral Codeine Sulfate in Pediatric Patients With Post-procedural Pain
- First Posted Date
- 2012-08-31
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 31
- Registration Number
- NCT01676493
- Locations
- 🇺🇸
Children's Medical Center Dallas, Dallas, Texas, United States